GlassScriptPhysician profile
Andrea Bushnell
NPI 1356904148
$14,894.19
in general payments reported to CMS, 2019-2025
60 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,542 · 2022: $1,592 · 2023: $1,901 · 2024: $7,415 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,115 · Travel and Lodging: $3,264 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,114.81 |
| Travel and Lodging | $3,263.89 |
| Education | $381.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,602.16 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $2,004.39 | 2024 | Infinity |
| Abbvie INC. | $1,148.15 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $667.79 | 2021-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $653.59 | 2021-2025 | Reyvow, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $611.59 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $561.76 | 2021-2025 | Nayzilam, Briviact, Zilbrysq |
| Biogen, INC. | $513.57 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Neurocrine Biosciences, INC. | $484.65 | 2022-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $427.46 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $399.91 | 2021-2025 | Vyepti, Rexulti |
| Eisai INC. | $372.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $325.78 | 2021-2025 | |
| Amgen INC. | $288.48 | 2021-2025 | Uplizna |
| Pfizer INC. | $268.29 | 2023-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Bushnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.